Background: Asprosin is correlated to many pathologic of glucose dysregulation, insulin resistance, β-cell dysfunction, serum lipids, and adiposity.Objective investigating the role of the asprosin hormone and its relationship to insulin resistance in newly diagnosed metabolic syndrome and clinical parameters.

Methods: The study included measurement of asprosin hormone, insulin, insulin resistance and some biochemical variable levels in metabolic syndrome patients with age matching to the control group (35 - 65 years). The study included the measurement of asprosin hormone. MetS were diagnosed in compliance with the European Group for the Study of Insulin Resistance (EGIR) criteria for patients attending the abdominal consultation unit at the Ibn Sina Teaching Hospital in Mosul, Iraq.

Results: The findings revealed a significant increase in the concertation of asprosin hormone in metabolic syndrome patients compared to the control group. Also, it has been found that was a significant increase in the concertation of glucose, insulin, homeostasis model for insulin resistance (HOMA-IR), Glucose to insulin Ratio(G/I), Triglyceride Glucose index (TyG), and McAuley Index, in addition to decreasing in homeostasis model for β-cell function(HOMA-%β), sensitivity of insulin(HOMA-%S) and Quantitative insulin sensitivity check index(QUICKI) in the metabolic syndrome patients. there is also a significant positive correlation between asprosin hormone with insulin resistance.

Conclusion: Findings indicated that serum levels of asprosin and insulin resistance are increased in patients with metabolic syndrome. Also, they have a relationship with clinical parameters. So asprosin hormone can be used new biomarker of metabolic turbulence.

Keywords: Asprosin; insulin; metabolic syndrome; insulin resistance